ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near Charlotte, NC, USA:

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Charlotte, North Carolina, United States and 123 other locations

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying E...

Enrolling
Non-Small Cell Lung Cancer
EGFR/HER2 Exon 20 Insertion Mutation
Drug: STX-721/PFL-721 (Escalated)
Drug: STX-721/PFL-721 (RP2D)

Phase 1, Phase 2

Pierre Fabre
Pierre Fabre

Charlotte, North Carolina, United States and 23 other locations

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. ...

Active, not recruiting
Lung Cancer, Non-squamous, Non-small Cell
Drug: carboplatin
Drug: zongertinib

Phase 3

Boehringer Ingelheim
Boehringer Ingelheim

Rock Hill, South Carolina, United States and 162 other locations

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

(SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Biological: Sacituzumab Govitecan-hziy (SG)
Drug: Docetaxel

Phase 3

Gilead Sciences
Gilead Sciences

Charlotte, North Carolina, United States and 226 other locations

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and...

Active, not recruiting
Non Small Cell Lung Cancer
Lung Cancer Stage III
Drug: Paclitaxel
Drug: Durvalumab

Phase 2

Wake Forest University (WFU)
Wake Forest University (WFU)

Charlotte, North Carolina, United States

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: TAK-788

Phase 1, Phase 2

Takeda
Takeda

Charlotte, North Carolina, United States and 61 other locations

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The pr...

Enrolling
Non-small Cell Lung Cancer
Other: Placebo
Biological: Intismeran autogene

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Charlotte, North Carolina, United States and 229 other locations

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (...

Enrolling
Non-Small Cell Lung Cancer
Drug: Domvanalimab
Drug: Durvalumab

Phase 3

AstraZeneca
AstraZeneca

Charlotte, North Carolina, United States and 261 other locations

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

Enrolling
Non Small Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma
Drug: Pemetrexed
Drug: Carboplatin + Pemetrexed

Phase 1, Phase 2

Phanes Therapeutics

Huntersville, North Carolina, United States of America and 5 other locations

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or...

Active, not recruiting
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Biological: Pembrolizumab
Biological: Ramucirumab

Phase 3

SWOG Cancer Research Network
SWOG Cancer Research Network

Charlotte, North Carolina, United States and 566 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems